Michael Kaseta
CIK 1724346 · CFO and COO · last filed 2026-10-13
Michael Kaseta is a CFO and COO who has filed 56 SEC Form 4 insider transactions across 4 companies since 2017. The most recent filing, for LQDA, was dated Oct 13, 2026. Across all open-market trades the lifetime net is −$18.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LQDA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
419 DAVIS DRIVE, SUITE 100
MORRISVILLE, NC 27560
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LQDA | CFO and COO | 340,148 | $47.87 | $16.28M | -$18.74M | 42 | 2026-10-13 |
| HRTX | Director | 53,960 | $0.37 | $20.0K | $0 | 4 | 2026-02-03 |
| ALIMERA SCIENCES INC (ALIM) Delisted | Director | — | $5.54 | — | $0 | 2 | 2023-10-04 |
| Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Chief Financial Officer | 15,000 | — | — | $0 | 2 | 2018-03-19 |
Recent Filings
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-13 | LQDA | Mixed | −6,061 | -$539.4K | EDGAR |
| 2026-07-14 | LQDA | Mixed | −7,551 | -$1.46M | EDGAR |
| 2026-04-16 | LQDA | Mixed | −52,419 | -$5.46M | EDGAR |
| 2026-04-15 | LQDA | Notice (144) | −139,390 | -$5.40M | EDGAR |
| 2026-04-14 | LQDA | Notice (144) | −3,000 | -$116.5K | EDGAR |
| 2026-04-14 | LQDA | Mixed | −6,080 | -$1.62M | EDGAR |
| 2026-04-13 | LQDA | Mixed | — | -$5.01M | EDGAR |
| 2026-04-10 | LQDA | Notice (144) | −23,821 | -$960.5K | EDGAR |
| 2026-04-09 | LQDA | Notice (144) | −133,789 | -$5.11M | EDGAR |
| 2026-03-03 | LQDA | Mixed | +1,179 | -$35.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.